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Background. Natalizumab is a highly effective treatment approved for multiple sclerosis (MS). The opening of the blood-brain
barrier mediated by matrix metalloproteinases (MMPs) is considered a crucial step in MS pathogenesis. Our goal was to verify
the utility of serum levels of active MMP-2 and MMP-9 as biomarkers in twenty MS patients treated with Natalizumab.Methods.
Serum levels of active MMP-2 andMMP-9 and of specific tissue inhibitors TIMP-1 and TIMP-2 were determined before treatment
and for 21 months of therapy. Results. Serum levels of active MMP-2 and MMP-9 and of TIMP-1 and TIMP-2 did not differ during
the treatment.The ratio betweenMMP-9 andMMP-2 was increased at the 15thmonth compared with the 3rd, 6th, and 9thmonths,
greater at the 18th month than at the 3rd and 6th months, and higher at the 21st than at the 3rd and 6th months. Discussion. Our
data indicate that an imbalance between activeMMP-9 and activeMMP-2 can occur inMS patients after 15 months of Natalizumab
therapy; however, they do not support the use of serum active MMP-2 and active MMP-9 and TIMP-1 and TIMP-2 levels as
biomarkers for monitoring therapeutic response to Natalizumab.
1. Introduction
Multiple sclerosis (MS) is a chronic inflammatory disease of
the central nervous system (CNS) of presumed autoimmune
origin that is characterized by demyelination and axonal
loss [1]. MS affects young adults, women more frequently
than men, and is clinically marked by exacerbations, called
relapses, which typically show dissemination in space and
time [2]. Brain inflammation is initiated and sustained by
lymphocyte migration across the blood-brain barrier (BBB)
[3]. In particular, the interaction of 𝛼4𝛽1 integrin on the
surface of lymphocytes with vascular-cell adhesion molecule
1 (VCAM-1) and on the surface of vascular endothelial cells
in brain and spinal cord blood vessels mediates the adhesion
and migration of lymphocytes in inflamed CNS sites [4].
Natalizumab (Tysabri, Biogen Idec Inc., Cambridge, Mas-
sachusetts, USA) is a humanized anti-𝛼4 integrinmonoclonal
antibody approved for relapsing-remitting multiple sclerosis
(RRMS) [5, 6].The efficacy of Natalizumabmonotherapy was
demonstrated in clinical trials by the reduction in relapse rate
and the progression of disability [7]. Consequently, Natal-
izumab is used as a second-line treatment inMS patients who
have a suboptimal response to first-line disease-modifying
therapies or as a first-line therapy in those with a highly active
disease [8]. Notwithstanding the unquestionable benefits,
anti-𝛼4 integrin treatment is, however, associated with John
Cunningham Virus- (JCV-) mediated progressive multifocal
leukoencephalopathy (PML), a severe adverse event [9].
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Although MS etiology remains largely unknown, the migra-
tion of immunocompetent cells into the CNS is dependent
on several factors, but it fundamentally requires the opening
of the BBB, a mechanism in which matrix metalloproteinases
(MMPs) play a crucial role [10, 11].These enzymes are a family
of zinc-containing and calcium-requiring endopeptidases,
which are secreted into extracellular space as a latent inac-
tive proform that becomes activated through a proteolytic
cleavage [12]. Specific tissue inhibitors of metalloproteinases
(TIMPs) are molecules capable of binding either activated
MMPs or their preforms and then finally of regulating
MMP activity [13]. Due to their ability to degrade type IV
collagen and gelatin, which are the main constituents of basal
lamina, MMP-2 (gelatinase A, 72 kDa type IV collagenase)
and MMP-9 (gelatinase B, 92 kDa type IV collagenase) are
the most extensively studied subfamily of MMPs in the
course of MS. In particular, previous studies demonstrated
that cerebrospinal fluid (CSF) and serum levels of MMP-
9 were higher in RRMS compared to progressive forms
[14–16] and that elevated CSF and serum concentrations of
MMP-9were associatedwith clinical andmagnetic resonance
imaging (MRI) evidence of disease activity [15, 17–19] and
disease evolution [20]. Moreover, CSF levels of MMP-9 were
reduced after 12 months of Natalizumab treatment in 7 MS
patients and in the same study CSFMMP-9 mean levels were
higher in MS patients before Natalizumab treatment than in
patients with other neurological diseases [21]. On the other
hand, the significance of MMP-2 is more controversial in
MS. In fact, while MMP-9 is predominantly upregulated in
inflammatory conditions, MMP-2 is constitutively expressed
in the brain [22]. Contradictory results have been reported in
previous studies where MMP-2 levels in acute and chronic
demyelinated lesions [23–25] as well as in CSF [26] in
serum [15, 17, 20] and in peripheral blood mononuclear cells
(PBMCs) [27–29] were increased, decreased, or represented
in equivalent amounts in MS patients and in controls. In
two previous studies we investigated the role of the active
forms of MMP-9 and MMP-2 in MS and our results showed
a reciprocal variation in these enzymes compared to the
activity of the disease. In particular, serum and CSF levels
and the intrathecal synthesis of active MMP-9 forms were
associatedwith clinical andMRI disease activity [30] whereas
CSF levels and intrathecal synthesis of active MMP-2 were
more elevated in MS patients without MRI evidence of
disease activity [31].
Considering these findings, in this study we, aimed to
investigate serum temporal concentrations of active MMP-
2 and active MMP-9 in a cohort of RRMS patients during 21
months of Natalizumab therapy.
2. Materials and Methods
2.1. Study Design and Sample Handling. The study design
and the sample population were the same as in an earlier
study [32]. Briefly, twenty consecutive RRMS [33] patients
(17 female and 3 male) in treatment with Natalizumab were
included in the study. All the patients were enrolled in the
“Fondazione Istituto Neurologico C. Mondino” in Pavia.
Serum samples were collected before starting therapy and
then every three months for 21 months of treatment. All
the samples were withdrawn, stored, and analyzed under
the same conditions. At any time point: (a) disease severity
was scored using Kurtzke’s Expanded Disability Status Scale
(EDSS) [34]; (b) presence of relapse was recorded as clinical
activity; and (c) anti-JCV antibodies were determined to
assess the risk of PML [35]. During the treatment, disability
progression was defined as an increase of one point on EDSS
score from baseline [5]. Brain MRI scans were performed at
entry and at the end of the study and the occurrence of a
new lesion on T2-weighted scans and/or a new gadolinium-
(Gd-) enhancing lesion on T1-weighted scans was defined
as MRI activity [33]. The approval of the Committee for
Medical Ethics in Research was obtained for experiments
involving human subjects. Written informed consent was
obtained from all subjects participating in the study.
2.2. MMP-2 and MMP-9 Activity Assays. Serum levels of
active MMP-2 and active MMP-9 were determined using
commercially available specific activity assay systems as
published before [30, 31] (Activity Assay System, Biotrak,
Amersham Biosciences, Little Chalfont, UK; code RPN2631
and code RPN2634, resp.). With these methods, only circu-
lating active forms of MMP-2 and MMP-9 were measured.
All the reagents and standards were included in the kits.
Briefly, in both activity assays, serum samples were applied
in duplicate into 96-microwell microtiter plates precoated
with anti-MMP-2 or anti-MMP-9 antibodies. Human pro-
MMP-2 and pro-MMP-9, respectively, activated with p-
aminophenylmercuric acetate, were used in six serial dilu-
tions, as standard, in each plate. The detection enzyme was
the proform of a modified urokinase, an enzyme that can
be activated by captured active MMPs in an active detection
enzyme. The natural activation sequence in the prodetection
enzyme was replaced using protein engineering, with an
artificial sequence recognized by specific MMP. Activated
urokinases were thenmeasured using a specific chromogenic
substrate (S-2444). The amount of active MMP-2 or active
MMP-9 in all samples was determined by interpolation
from a standard curve. According to the manufacturer’s
instructions, for the MMP-2 activity assay, the lower limit
of quantification was 0.19 ng/mL, the range of intra-assay
coefficient of variations (CV) was 4.4–7.0%, and the range
of interassay CV was 16.9–18.5%, while for the MMP-9
activity assay the lower limit of quantification was assumed at
0.125 ng/mL, the range of intra-assay CV was 3.4–4.3%, and
the range of interassay CV was 20.2–21.7%.
2.3. TIMP-1 and TIMP-2 Detection Assays. As previously
described [30, 31], serum levels of TIMP-1 and TIMP-
2 were measured using commercially available “sandwich”
ELISA kits (Biotrak, Amersham Biosciences, Little Chalfont,
UK; codes RPN2611 and RPN2618, resp.) according to the
manufacturer’s instructions. All the reagents and standards
were included in the kits. The limit of sensitivity in both the
assays was 3.13 ng/mL.
2.4. Data Analysis. Statistical analysis was performed with
GraphPad Prism. The normality of each variable was
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Table 1: Demographic and clinical characteristics of 20 RRMS
patients stratified according to response to therapy before and
during treatment with Natalizumab.
Responders Nonresponders
Patients (𝑛) 15 5
Sex (male/female) 3/12 0/5
Age at entry, years (mean ± SD) 35.1 ± 10.1 31.6 ± 9.4
EDSS at baseline (mean ± SD) 1.0 ± 1.1 2.3 ± 2.4
EDSS after 21 months of therapy 1.3 ± 1.3 2.8 ± 2.4
Relapses during 21 months of
therapy (mean ± SD) 0 1.6 ± 0.9
Patients with new MRI lesions at
the end of treatment 4 0
EDSS = Expanded Disability Status Scale; MRI = magnetic resonance
imaging; SD = standard deviation.
checked by using the Kolmogorov-Smirnov test. When
normality of data distribution was found in all variables,
statistical analysis was performed by a parametric approach.
Accordingly, ANOVA test was used to compare variables
among the various groups, and when significant differences
were found, Student’s 𝑡-test was used for the comparison
between two groups. On the other hand, when normality
of data distribution was rejected, statistical analysis was
performed by a nonparametric approach. Kruskal-Wallis test
was used to compare variables among the various groups and
if significant differences were found, Mann-Whitney 𝑈-test
was then used to compare two different groups. In case of
multiple comparisons, a Bonferroni post hoc correction was
applied. A value of 𝑝 < 0.05 was accepted as significant.
3. Results
Demographic and clinical characteristics of 20 RRMS
patients treatedwithNatalizumab are listed in Table 1. During
the therapy five patients experienced relapses (3 patients
had 1 relapse between baseline and 3 months, one had 2
relapses between 6 and 9 months and at 12 months, and
one had 2 relapses between 9 and 12 months and between
18 and 21 months) and four patients showed new T2 and/or
Gd-enhancing lesions on the last MRI examination at the
21st month. No patients showed anti-JCV seroconversion
during the 21 months of Natalizumab treatment. The tim-
ing of sample collection was not sequential and resulted
incomplete for ten patients. However, we decided to analyze
all the variables in RRMS patients considered as a whole.
Serum levels of active MMP-2, active MMP-9, and TIMP-1
were detected in all samples, while serum levels of TIMP-
2 were measured in 145/148 (98%) of samples. As reported
in Figure 1, no differences were found for serum levels of
active MMP-2 (panel (a), ANOVA: n.s.) and active MMP-
9 (panel (b), Kruskal-Wallis: n.s.) and TIMP-2 (panel (c),
Kruskal-Wallis: n.s.) and TIMP-1 (panel (d), ANOVA: n.s.)
among the various time points. The ratios between MMPs
and the specific tissue inhibitors and between active MMP-9
and active MMP-2 were then calculated for all the patients at
each time point (Figure 2). No differences were found for the
MMP-2/TIMP-2 (panel (a), Kruskal-Wallis: n.s.) and MMP-
9/TIMP-1 (panel (b), Kruskal-Wallis: n.s.) ratios while the
active MMP-9/active MMP-2 ratio was different at various
time points (panel (c), Kruskal-Wallis: 𝑝 < 0.001) and in
particular it was higher at the 15th month (Mann-Whitney
with Bonferroni correction) than at the 3rd (𝑝 < 0.01), 6th
(𝑝 < 0.01), and 9th months (𝑝 < 0.05), more elevated at the
18th month than at the 3rd and 6th (𝑝 < 0.05), and finally
more increased at the 21st month of treatment than at the 3rd
and 6th months (𝑝 < 0.05). Afterwards, we tried to compare
patients who were free of relapses during the treatment,
considered as “responders,” with patients who experienced at
least one relapse, “nonresponders.” Despite the small number
of patients in each group, we compared all the variables:
serum concentrations of active MMP-2 and active MMP-9
and TIMP-2 and TIMP-1 and the ratios calculated between
MMPs and TIMPs and between active MMP-9 and active
MMP-2. No differences were found between the responders
and the nonresponders for all the data analyzed (data not
shown).
4. Discussion
To the best of our knowledge, this is the first study that
longitudinally analyzes serum levels of active MMP-2 and
activeMMP-9with sensitive activity assay systems in a cohort
of RRMS patients during the treatment with Natalizumab in
an attempt to provide further insight into the real significance
of gelatinases in MS pathology and their role in monitoring
efficacy of treatment.The involvement of MMP-2 andMMP-
9 in MS pathogenesis and progression has been widely
investigated in the past decades. There is a large agreement,
particularly on the proinflammatory role of MMP-9 and
on the protective function of TIMP-1. In particular, serum
MMP-9 levels were greater in RRMS than in the progressive
forms [14–16] in MS patients with MRI evidence of disease
activity [15, 17, 19] and in MS subjects with clinically isolated
syndromes who developed clinically definite MS [18]. On
the other hand, TIMP-1 levels were lower in MS patients
than in controls [14, 15, 17] and serum MMP-9/TIMP-1 ratio
has been indicated as a potential biomarker of MS disease
activity [15, 18]. The study of the active forms of MMP-9
also demonstrated that CSF and serum levels of active MMP-
9 could represent a potential biomarker for monitoring MS
disease activity and that serum active MMP-9/TIMP-1 ratio
seems to be an indicator of ongoing MS inflammation [30].
In addition, beneficial effects of Natalizumab treatment were
associated with decreased CSFMMP-9 levels after 12 months
of therapy, and for this reason MMP-9 was proposed as
a biomarker for clinical trials on new drugs for MS [21].
On the contrary, the role of MMP-2 still remains unclear.
Previous studies have reported that MMP-2 was elevated
in PBMCs and CD4+ Th1 cells of MS patients and could
contribute to the homing of these immune cells inside the
brain through the BBB [28, 29]. In addition, while CSFMMP-
2 levels appeared to be comparable between MS and controls
[14, 15, 22, 25, 26], serumMMP-2 concentrations were similar
or lower in MS patients than in controls [15, 20]. The active
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Figure 1: Longitudinal fluctuations of serum active MMP-2 (a) and active MMP-9 and (b) TIMP-2 (c) and TIMP-1 (d) in patients with
relapsing-remitting multiple sclerosis (RRMS) treated with Natalizumab for 21 months. MMP = matrix metalloproteinases; TIMP = tissue
inhibitors of metalloproteinases; T0 = baseline; T3 = 3rd month; T6 = 6th month; T9 = 9th month; T12 = 12th month; T15 = 15th month; T18
= 18th month; and T21 = 21st month. Horizontal bars indicate medians and error bars correspond to interquartile range. The boundaries of
the box represent the 25th–75th quartiles. The line within the box indicates the median. The whiskers above and below the box correspond
to the highest and lowest values, excluding outliers.
form of MMP-2 has been described as a potential marker
of MS recovery, as detected by MRI, suggesting a beneficial
function that sustains the resolution of the inflammatory
response and the remission of the disease [31]. In the present
study, serum levels of active MMP-2 and active MMP-9
and of the specific tissue inhibitors TIMP-2 and TIMP-1,
respectively, were found to be stable during the 21 months of
Natalizumab therapy in all patients. Surprisingly, despite the
small number of patients included in the study, we did not
find differences between patients who experienced relapses
during the treatment, considered as “nonresponders,” and
patients thatwere free of relapses, considered as “responders,”
for activeMMP-2 and activeMMP-9 and TIMP-2 and TIMP-
1 serum levels at each time point. Moreover, the ratios
between active MMPs and the respective TIMPs did not
appear influenced by the Natalizumab treatment and did not
differ between responders and nonresponders during the 21
months of observation. On the one hand, this could indicate
that Natalizumab treatments maintain stable serum levels of
MMPs and TIMPs, but, on the other hand, this excludes the
use of these molecules in monitoring the pharmacological
response. Previous studies on recombinant interferon beta-
1a, one of the most used disease-modifying therapies for
MS, showed that low MMP-9 serum levels were associated
with a positive outcome, while MMP-2 serum levels were
stable during treatment [36] and that serum MMP-9/TIMP-
1 ratio may be regarded as a reliable marker and may be
predictive of MRI activity in RRMS [37]. Moreover, TIMP-
1 has also been suggested as a good indicator of response to
therapy [38]. Our principal finding was that an imbalance
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Figure 2: Longitudinal fluctuations of serum active MMP-2/TIMP-2 ratio (a), serum active MMP-9/TIMP-1 ratio (b), and serum active
MMP-9/active MMP-2 ratio (c) in relapsing-remitting multiple sclerosis (RRMS) patients during 21 months of Natalizumab treatment. No
differences were found for the MMP-2/TIMP-2 (a) and MMP-9/TIMP-1 (b) ratios while the active MMP-9/active MMP-2 ratio was different
at various time points ((c), 𝑝 < 0.001); in particular it was higher at the 15th month than at the 3rd (1𝑝 < 0.01), 6th (2𝑝 < 0.01), and 9th
months (3𝑝 < 0.05), increased at the 18th month than at the 3rd and 6th (4,5𝑝 < 0.05), and more elevated at the 21st month of treatment than
at the 3rd and 6th months (6,7𝑝 < 0.05). MMP = matrix metalloproteinases; TIMP = tissue inhibitors of metalloproteinases; T0 = baseline;
T3 = 3rd month; T6 = 6th month; T9 = 9th month; T12 = 12th month; T15 = 15th month; T18 = 18th month; and T21 = 21st month. Horizontal
bars indicate medians and error bars correspond to interquartile range.The boundaries of the box represent the 25th–75th quartiles. The line
within the box indicates the median. The whiskers above and below the box correspond to the highest and lowest values, excluding outliers.
occurred between active MMP-9 and active MMP-2 serum
levels after 15months of Natalizumab therapy without further
differences between responder and nonresponder patients.
The ratio between MMP-9 and MMP-2 was proposed as a
serum marker to monitor the progression of liver disease,
and the ratio between MMP-2 and MMP-9 was associated
with poor response to chemotherapy in osteosarcoma in two
previous studies [39, 40]; however this is the first time that
the ratio between the active forms of MMP-9 and MMP-2
was calculated in MS patients, and for this reason further
studies are required to investigate the biological significance
of the imbalance between serum levels of gelatinases. The
main limitations of this study were the small number of
enrolled patients and above all the lack of samples collected
at the time of relapse. In conclusion, taken together, our data
seems to indicate that Natalizumab treatment could either
maintain serum levels of activeMMP-2 and activeMMP-9, as
well as of the specific tissue inhibitors TIMP-1 and TIMP-2,
stable ormake themnot affected at all; however, this influence
tends to be reduced after 15 months of therapy resulting in
an imbalance between serum active MMP-9, considered as
a marker of disease activity [30], and serum active MMP-2,
described as a marker of disease remission [31]. Moreover,
the present study argues against the use of serum levels of
6 Disease Markers
gelatinases for the monitoring of Natalizumab treatments in
MS patients. Nevertheless, more extensive research in a larger
number of patients is advisable for a better understanding
of the correlations between Natalizumab therapy and gelati-
nases in MS.
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